

South Carolina
Department of Health and Human Services
Post Office Box 8206
Columbia, South Carolina 29202-8206

Pharmacy and Therapeutics (P&T) Committee Meeting
May 7, 2014
MINUTES

1. Call to Order

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, May 7, 2014.

2. Welcome

Edward Behling, MD, called the meeting to order and welcomed members, guests, and staff members.

Dr. Behling opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

3. Committee Members Present:

Gregory Browning, MD
James Lindsey, MD

Tan Platt, MD
Edward Behling, MD

Jony Bollinger, MD
Kelly Jones, PharmD

SC DHHS Staff:

Jim Assey, R.Ph.
Janet Giles
Marion Burton, MD
Bryan Amick, PharmD, MBA
Constance Holloway, JD
Jim Bradford, MD

Magellan Medicaid Admin:

Lisa Correll, PharmD
Lori Ash

4. Discussion Topics

A. Committee Meeting Minutes, Wednesday, February 5, 2014

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

B. Public Comment

Company	Speaker	Drug/Class
Bristol-Myers Squibb	Manan Shah, PharmD, PhD	Anticoagulants, Oral
Johnson & Johnson	Phillip Wiegand, PharmD, MS	Anticoagulants, Oral
Gilead Sciences, Inc.	Ray Lancaster, PharmD	Hepatitis C

C. Drug Classes for Review

Lisa Correll led the discussion for the following drug classes:

Classes for Re-Review

- Antihistamines, Minimally Sedating
- Thiazolidinediones (TZDs)
- Sulfonylureas (Metformin (Biguanide) Combination Agents)
- Bronchodilators Beta Agonist, Short Acting Nebulizers
- Anticoagulants, Oral
- Proton Pump Inhibitors
- Smoking Cessation

Classes for Review

- Antibiotics, Inhaled

The chart below represents the recommendations from the P & T Committee:

ANTIHISTAMINES, MINIMALLY SEDATING	
Preferred	Non-Preferred
Cetirizine	Allegra®
Fexofenadine*	Clarinex®
Loratadine	Claritin®
	Desloratadine
	Levocetirizine
	Xyzal®
	Zyrtec®
*Liquids and orally disintegrating formulations Limited to patients age 12 and under.	

THIAZOLIDINEDIONES (TZDs)	
Preferred	Non-Preferred
Pioglitazone	Actos®
	ActosPlus® Met
	ActosPlus® Met XR
	Avandamet®
	Avandaryl®

THIAZOLIDINEDIONES (TZDs) <i>(continued)</i>	
Preferred	Non-Preferred
	Avandia® Duetact®

SULFONYLUREAS	
Preferred	Non-Preferred
Glimepiride Glipizide Glyburide Glyburide/Metformin	Amaryl® Diabeta® Glucotrol® / Glucotrol® XL Glucovance® Glynase PresTab® Metformin/Glipizide (Metaglip)

BRONCHODILATORS BETA AGONIST, SHORT ACTING NEBULIZERS	
Preferred	Non-Preferred
Albuterol Nebulizer Inhalation	Xopenex®

ANTICOAGULANTS, ORAL	
Preferred	Non-Preferred
Warfarin Pradaxa® Eliquis® Xarelto®	Coumadin® Jantoven®

PROTON PUMP INHIBITORS (PPIs)	
Preferred	Non-Preferred
Omeprazole Pantoprazole Nexium® Suspension	Aciphex® Dexilant® Esomeprazole Strontium Lansoprazole Nexium® Prilosec® Prevacid® Protonix® Zegerid®
<i>*Disintegrating Lansoprazole will continue to be available without PA for patients age 12 and under</i>	

SMOKING CESSATION	
Preferred	Non-Preferred
Bupropion SR Chantix® / Dose Pack Nicotine Gum	NicoDerm® CQ Patch Nicorette® Gum Nicorette® Lozenge

SMOKING CESSATION (<i>continued</i>)	
Preferred	Non-Preferred
Nicotine Lozenge Nicotine Patch	Nicotrol® Inhalation Nicotrol®NS Nasal Zyban®

ANTIBIOTICS, INHALED	
Preferred	Non-Preferred
Bethkis® TOBI Inhalation®	Cayston® TOBI Podhaler® Tobramycin Solution Inhalation

5. **Old Business**

None

6. **New Business**

Bryan presented information on draft PA criteria for the treatment of Hepatitis C. In addition, he advised the Committee of upcoming changes to the Lock-In program. These changes will be adopted on July 1, 2014.

Bryan advised the Committee that most payers have 2 preferred options for diabetic supplies and it is advantageous for FFS to implement that methodology. Special provisions will continue to be made for those whose clinical condition warrants special consideration. Manufacturers will be invited to speak at the next P&T meeting.

SC DHHS plans to implement Phase 2 of the VBID (Valued Based Design) plan soon. This phase will introduce a two tier copay structure. SC DHHS is currently working through the process of amending the SC Medicaid State Plan to allow for more flexibility in patient cost share.

7. **Resolved Items**

Recommendations regarding PDL status for drugs in the following classes were approved for submission to DHHS.

- Antihistamines, Minimally Sedating
- Thiazolidinediones (TZDs)
- Sulfonylureas (Metformin (Biguanide) Combination Agents)
- Bronchodilators Beta Agonist, Short Acting Nebulizers
- Anticoagulants, Oral
- Proton Pump Inhibitors
- Smoking Cessation
- Antibiotics, Inhaled

8. Closing Comments

The next meeting will be held on Wednesday, August 6, 2014, at 4:00 p.m.

9. Adjournment

The meeting adjourned at 6:29 p.m.